martes, 7 de junio de 2016
Cancer Currents Blog: Two New Therapies Approved by FDA for Advanced Kidney Cancer
Cabozantinib and lenvatinib for kidney cancer - National Cancer Institute
The Food and Drug Administration (FDA) recently approved two drugs for the treatment of patients with advanced kidney cancer. Both approvals are for patients whose cancers have progressed after receiving prior treatment with drugs that block tumor blood vessel growth, known as antiangiogenic therapies. On April 15, the agency approved cabozantinib(Cabometyx™), and on May 13 it approved lenvatinib (Lenvima®) in combination witheverolimus (Afinitor®).